Who is the CEO of Ahn-gook Pharmaceutical?

According to the DART company overview, Ahn-gook Pharmaceutical's representative director is 어진, 박인철 (각자 대표) (name as registered in Korean). The company was founded on 1959-02-12.

Where is Ahn-gook Pharmaceutical listed?

Ahn-gook Pharmaceutical trades on the Korea Exchange KOSDAQ market under the ticker 001540. Its fiscal year ends in December.

Does Ahn-gook Pharmaceutical pay a dividend?

Yes. For fiscal 2025, Ahn-gook Pharmaceutical paid a cash dividend of ₩633 per common share, a 7.0% yield as stated in its annual report, with a payout ratio of 93.3%. The prior year's dividend was ₩440.

Does Ahn-gook Pharmaceutical have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Profit +50% (latest quarterly operating profit up more than 50% year on year); Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year); High dividend (reported dividend yield of 5% or more in the latest annual report); Dividend grower (dividend per share raised three years in a row). These are factual flags, not investment advice.

Which companies are in the same industry as Ahn-gook Pharmaceutical?

Under the Korean Standard Industrial Classification recorded on DART, Ahn-gook Pharmaceutical is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.

Ahn-gook Pharmaceutical KRX:001540KOSDAQ

안국약품 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days9

DART filings, 7 days0

Articles tracked47since Sep 11

In Q2 2026, Ahn-gook Pharmaceutical reported revenue of ₩91.9bn, up 19.6% year on year, and operating profit of ₩8.6bn. Ahn-gook Pharmaceutical (안국약품) appeared in 9 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 21 with 9 articles. It was most often mentioned alongside DongKookPharmaceutical.

Filing signals Profit +50% Revenue & profit growth High dividend Dividend grower Screener

Ahn-gook Pharmaceutical quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩91.9bn	+19.6%	₩8.6bn margin 9.4%	₩8.6bn
Q1 2026	₩98.9bn	+30.6%	₩16.0bn margin 16.2%	₩12.4bn
Q4 2025 derived	₩76.6bn	+8.4%	−₩5.9bn margin −7.7%	−₩2.6bn
Q3 2025	₩77.7bn	+15.1%	₩4.9bn margin 6.3%	₩3.4bn
Q2 2025	₩76.8bn	+14.4%	₩5.0bn margin 6.5%	₩3.1bn
Q1 2025	₩75.8bn	+15.2%	₩5.9bn margin 7.7%	₩3.5bn
Q4 2024 derived	₩70.7bn	+10.1%	₩1.2bn margin 1.8%	−₩657m
Q3 2024	₩67.5bn	+22.0%	₩708m margin 1.0%	−₩372m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Ahn-gook Pharmaceutical top stories 2 weeks, by number of outlets

1
안국약품, 피부미용사업부 신설…메디컬에스테틱 진출 본격화
5 outlets · 5 articlesFirst report Oct 21 09:21 메디파나뉴스
2
안국약품, ‘페바로젯 저용량·레보살탄플러스’ 출시 기념 심포지엄 개최
2 outlets · 2 articlesFirst report Oct 27 09:34 더바이오
3
안국약품, 과천 업무시설에 또 1630억…장기 재원 확보 과제
1 outlets · 1 articlesFirst report Oct 19 11:50 메디파나뉴스
4
안국약품, 메디컬에스테틱 시장 진출 본격화…신사업 확대 시동
1 outlets · 1 articlesFirst report Oct 21 09:40 메디팜스투데이
5
안국약품, 메디컬 에스테틱 진출 본격화…피부미용 사업부 신설
1 outlets · 1 articlesFirst report Oct 21 09:52 더바이오
6
[Pharma Report] 안국약품, 필러·스킨부스터로 피부미용 사업 시동 外
1 outlets · 1 articlesFirst report Oct 21 12:30 헬스코리아뉴스

Latest Ahn-gook Pharmaceutical news Korean headlines

Oct 2712:20

안국약품, CORE 심포지엄서 순환기 신제품 임상 성과 선봬
PRESS9
Oct 2711:06

순환계용약 '선택지 넓힌' 안국약품, 영역 확장 본격화
의협신문
Oct 2710:51

안국약품, 이상지질혈증 중강도 스타틴 전략 등 조명
의학신문(보사)
Oct 2710:45

안국약품, ‘CORE 심포지엄’ 개최
메드월드뉴스
Oct 2710:27

안국약품, 이상지질혈증·고혈압 치료 전략 공유…CORE 심포지엄 성료
메디코파마
Oct 2709:34
안국약품, 저용량 '페바로젯'·'레보살탄플러스' 출시…CV 확장
메디파나뉴스
1 more on this story · 1 outlets
- 안국약품, 페바로젯 저용량·레보살탄플러스 출시 심포지엄 개최메디칼업저버 · Oct 27 16:31
Oct 2709:13

안국약품, 'CORE 심포지엄'서 페바로젯·레보살탄플러스 임상 성과 공유
메디컬투데이
Oct 2416:01

"필러시장 진출"…안국약품, 피부미용사업부 신설
뉴시스경제
Oct 2309:14

[쩐의흔적] 안국약품 다섯 남매 지분 48%…어진 대표, 주식 담보로 13억원 빌렸다
더퍼블릭
Oct 2309:00

안국약품, 대진대 학생들 대상으로 한 기업탐방 프로그램 진행
IT비즈뉴스
Oct 2209:30

안국약품, 피부미용사업부 신설…메디컬에스테틱 진출
비건뉴스
Oct 2113:21

안국약품, 메디컬에스테틱 사업 진출
지디넷코리아
Oct 2112:30

[Pharma Report] 안국약품, 필러·스킨부스터로 피부미용 사업 시동 外
헬스코리아뉴스
Oct 2109:52

안국약품, 메디컬 에스테틱 진출 본격화…피부미용 사업부 신설
더바이오
Oct 2109:40

안국약품, 메디컬에스테틱 시장 진출 본격화…신사업 확대 시동
메디팜스투데이
Oct 2109:21
안국약품, 피부미용사업부 신설…메디컬에스테틱 진출 본격화
메디파나뉴스
4 more on this story · 4 outlets
- 안국약품, 메디컬에스테틱 사업 진출 본격화메드월드뉴스 · Oct 21 10:19
- 안국약품, 피부미용사업부 신설… 메디컬에스테틱 시장 출사표보건신문 · Oct 21 10:53
- 안국약품, 피부미용사업부 신설…메디컬에스테틱 시장 진출메디코파마 · Oct 21 13:56
- 안국약품, 메디컬에스테틱 사업 진출 본격화 外의약뉴스 · Oct 21 17:17
Oct 1911:50

안국약품, 과천 업무시설에 또 1630억…장기 재원 확보 과제
메디파나뉴스
Oct 1806:00

[제약공시 책갈피] 10월 3주차 - 동국제약·안국약품 外
메디파나뉴스DongKookPharmaceutical
Oct 1713:01

"제약업 이해"…안국약품, 취준생 기업탐방 진행
뉴시스경제
Oct 1608:11

안국약품, 과천 '메디파크원'에 1630억 투자…업무시설 확보
PRESS9
Oct 1605:53

안국약품도 1630억 투자, 막계동 '제2 과천지식정보타운' 될까
약사공론
Oct 1518:01

[HIT알공] 네이처셀·안국약품, 나란히 과천 부동산 취득 계약
히트뉴스Naturecell
Oct 1517:50

안국약품, 과천 업무시설 1630억원에 취득…총자산 52.4%
더바이오
Oct 1514:16

안국약품, 대학생 대상 기업탐방 진행
청년의사
Oct 1512:28

[Pharma Report] 동국제약, 안국약품, 대웅제약 하이닥, 셀트리온, 한국오가논, 한국다이이찌산쿄, 휴메딕스 등
헬스코리아뉴스Celltrion Daewoong Pharma DongKookPharmaceutical Humedix
Oct 1511:08

안국약품, 대진대 취업준비생 대상 기업 탐방 프로그램 진행
더바이오
Oct 1509:18

안국약품, 대진대 학생에 제약업 취업·직무 체험 지원
PRESS9
Oct 1509:15
안국약품, 대진대 제약업 취업준비생 위한 기업탐방 진행
메드월드뉴스
1 more on this story · 1 outlets
- 안국약품, 대진대 취업준비생 대상 기업탐방 진행보건신문 · Oct 15 11:31
Oct 1509:13

안국약품, 대진대생 기업탐방…제약업 취업 지원
메디파나뉴스
Sep 2311:18

안국문화재단(안국약품), ‘산으로 올라간 배’展 개최
메드월드뉴스

Articles per day 2 weeks

117

118

119

921

122

223

124

827

Company profile

CEO: 어진, 박인철 (각자 대표)
Industry: Pharmaceuticals
Founded: 1959-02-12
Fiscal year-end: December
Head office: 경기도 과천시
Website: ahn-gook.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Ahn-gook Pharmaceutical dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩633	7.0%	93.3%
FY2024	₩440	6.6%	29.7%
FY2023	₩220	2.6%	193.8%

Raised 3 years in a row

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

어진48.22%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Pharmaceuticals

All in industry

Company	Latest quarter op. profit	Articles 30d
Hanmi Pharm	₩131bn	655
Yuhan	₩66.9bn	484
Daewoong Pharma	₩68.1bn	372
GC Biopharma	₩1.7bn	326
DongKookPharmaceutical	₩26.1bn	259
Daewon Pharmaceutical	−₩9m	198
Kwangdong Pharmaceutical	₩2.8bn	188
JW Pharmaceutical	₩33.3bn	185

Compare Ahn-gook Pharmaceutical side by side with these companies

Ahn-gook Pharmaceutical DART filings

Oct 2117:15

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Oct 1517:14

Other 주요사항보고서(유형자산양수결정)
Other
Sep 1116:16

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports

Mentioned alongside 2 weeks

1 DongKookPharmaceuticalKOSDAQ 1

Ahn-gook Pharmaceutical FAQ

Who is the CEO of Ahn-gook Pharmaceutical?: According to the DART company overview, Ahn-gook Pharmaceutical's representative director is 어진, 박인철 (각자 대표) (name as registered in Korean). The company was founded on 1959-02-12.
Where is Ahn-gook Pharmaceutical listed?: Ahn-gook Pharmaceutical trades on the Korea Exchange KOSDAQ market under the ticker 001540. Its fiscal year ends in December.
What were Ahn-gook Pharmaceutical's latest quarterly results?: In Q2 2026, Ahn-gook Pharmaceutical reported revenue of ₩91.9bn, up 19.6% year on year, and operating profit of ₩8.6bn. Figures come from reports filed on DART.
Does Ahn-gook Pharmaceutical pay a dividend?: Yes. For fiscal 2025, Ahn-gook Pharmaceutical paid a cash dividend of ₩633 per common share, a 7.0% yield as stated in its annual report, with a payout ratio of 93.3%. The prior year's dividend was ₩440.
Does Ahn-gook Pharmaceutical have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Profit +50% (latest quarterly operating profit up more than 50% year on year); Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year); High dividend (reported dividend yield of 5% or more in the latest annual report); Dividend grower (dividend per share raised three years in a row). These are factual flags, not investment advice.
Which companies are in the same industry as Ahn-gook Pharmaceutical?: Under the Korean Standard Industrial Classification recorded on DART, Ahn-gook Pharmaceutical is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.